BIB

Fund Description
ProShares Ultra Nasdaq Biotechnology seeks daily investment results before fees and expenses that correspond to twice (200%) the daily performance of the NASDAQ Biotechnology Index.
Fund Profile
Fund Name ProShares Ultra Nasdaq Biotechnology
Fund Exchange Ticker BIB
Fund Sponsor ProShares
Fund ISIN US74347R2141
Net Expense Ratio 0.95 %
Fund Inception Date 7 April 2010
Fund Legal Structure ETF (Open end fund)
Exchange NASDAQ
Listing Country Code US
Fund Investment Objective
ETF Type Specific Leveraged / Inverse
Asset Class Equities (Stocks)
Index Linked Passive
Index Name Nasdaq Biotech Index
Index Provider Nasdaq
Currency Hedged No
Inverse / Leveraged Leveraged (2x)
Developed / Emerging Developed Market Funds
Market Capitalization Range Broad Market / Multi-Cap
Growth Value Core / Blend
Continent North America
Key Statistics
Return As of Date 16 January 2019
Asset Under Management 268.21 Million (USD)
1 Month Total Return 11.38 %
Year To Date Return 26.25 %
1 Year Total Return -11.46 %
3 Year Annualized Total Return 0.45 %
NAV 53.11
Share Outstanding 5,050,000
Top 10 Holdings (16 January 2019)
Constituent Name Constituent Ticker Constituent Type Weighting
IRONWOOD PHARMACEUTICALS INC IRWD EQUI
OPKO HEALTH INC OPK EQUI
MYRIAD GENETICS INC MYGN EQUI
MEDPACE HOLDINGS INC MEDP EQUI
ARENA PHARMACEUTICALS INC ARNA EQUI
ENDO INTERNATIONAL PLC ENDP EQUI
ARGENX SE - ADR ARGX EQUI
HALOZYME THERAPEUTICS INC HALO EQUI
AMICUS THERAPEUTICS INC FOLD EQUI
LIGAND PHARMACEUTICALS LGND EQUI